We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.56%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.98B
AUM Growth
+$247M
Cap. Flow
+$143M
Cap. Flow %
7.22%
Top 10 Hldgs %
27.18%
Holding
159
New
18
Increased
48
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$33.7M
2
UNH icon
UnitedHealth
UNH
+$26.1M
3
AET
Aetna Inc
AET
+$23.7M
4
MRSN
Mersana Therapeutics
MRSN
+$21.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$18.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$27.3M
2
SHPG
Shire pic
SHPG
+$24.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.9M
4
AMGN icon
Amgen
AMGN
+$16.1M
5
PTHN
Patheon N.V.
PTHN
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 79.63%
2 Financials 3.78%
3 Consumer Discretionary 1.13%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGN.PRA
101
DELISTED
Allergan plc
AGN.PRA
$4.34M 0.22%
5,000
– –
EXEL icon
102
Exelixis
EXEL
$13.3B
$4.31M 0.22%
175,000
– –
GBT
103
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.1M 0.21%
150,000
– –
OTIC
104
DELISTED
Otonomy, Inc.
OTIC
$3.96M 0.2%
210,000
– –
MGNX icon
105
MacroGenics
MGNX
$247M
$3.94M 0.2%
225,000
– –
ADAP
106
DELISTED
Adaptimmune Therapeutics
ADAP
$3.93M 0.2%
875,000
– –
HRC
107
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$3.58M 0.18%
45,000
– –
ALGN icon
108
Align Technology
ALGN
$12.3B
$3.45M 0.17%
+23,000
New +$3.12M
BLUE
109
DELISTED
bluebird bio
BLUE
$3.36M 0.17%
2,470
+115
+5% +$139K
CGEN icon
110
Compugen
CGEN
$218M
$3.13M 0.16%
825,000
– –
ALKS icon
111
Alkermes
ALKS
$8.12B
$3.01M 0.15%
52,000
-73,000
-58% -$4.24M
SIOX
112
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.9M 0.15%
+15,625
New +$2.74M
BMY icon
113
Bristol-Myers Squibb
BMY
$130B
$2.79M 0.14%
50,000
-402,600
-89% -$21.9M
RIGL icon
114
Rigel Pharmaceuticals
RIGL
$732M
$2.73M 0.14%
100,000
– –
ZBH icon
115
Zimmer Biomet
ZBH
$18.7B
$2.71M 0.14%
21,733
– –
DBVT
116
DBV Technologies
DBVT
$822M
$2.61M 0.13%
7,300
– –
GKOS icon
117
Glaukos
GKOS
$10B
$2.59M 0.13%
62,500
– –
INVA icon
118
Innoviva
INVA
$1.6B
$2.56M 0.13%
200,000
-35,000
-15% -$439K
HQY icon
119
HealthEquity
HQY
$8.7B
$2.54M 0.13%
51,000
+1,000
+2% +$46.8K
CBIO
120
Crescent Biopharma
CBIO
$588M
$2.51M 0.13%
+2,250
New +$1.86M
GNCA
121
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.51M 0.13%
60,000
– –
MCRB icon
122
Seres Therapeutics
MCRB
$47.5M
$2.49M 0.13%
11,000
– –
ITCI
123
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.33M 0.12%
187,500
-2,500
-1% -$29K
CDTX
124
DELISTED
Cidara Therapeutics
CDTX
$2.25M 0.11%
15,000
– –
KA
125
DELISTED
Kineta, Inc. Common Stock
KA
$2.11M 0.11%
3,214
– –
3 4
5
6 7

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

Rock Springs Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Rock Springs Capital Management held 159 positions worth $1.98B, up 14% from $1.73B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $143M of net new capital in Q2 2017, opening 18 new positions and adding to 48 existing holdings. Its largest new stake was Medtronic: 400,000 shares worth $35.5M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $21.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2017 buy was Medtronic: 400,000 shares worth $35.5M.
  • Rock Springs Capital Management added most to UnitedHealth in Q2 2017, an estimated $26.1M increase.
  • Rock Springs Capital Management's biggest Q2 2017 reduction was Bristol-Myers Squibb, cutting an estimated $21.9M.
  • Rock Springs Capital Management fully exited Eli Lilly in Q2 2017, selling an estimated $27.3M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.98B portfolio in Q2 2017.
  • Rock Springs Capital Management opened 18 new positions and closed 10 in Q2 2017.
  • Rock Springs Capital Management's portfolio value rose 14% quarter-over-quarter to $1.98B.

Based on Rock Springs Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.